ORLANDO (EGMN) - Two studies have shown promising results with systemic therapies for hepatocellular carcinoma, the investigators reported at a meeting on gastrointestinal cancers sponsored by the American Society of Clinical Oncology.In a post hoc analysis of the Sorafenib HCC Assessment Randomized Protocol (SHARP) trial, a subgroup of patients with advanced hepatocellular carcinoma who were also infected with hepatitis C showed the same benefit from treatment with sorafenib (Nexavar) as did patients...